Craft

Co-Diagnostics

Stock Price

$1.2

2024-10-29

Market Capitalization

$38.6 M

2024-10-29

Revenue

$622.5 K

FY, 2025

Co-Diagnostics Summary

Company Summary

Overview
Co-Diagnostics is a molecular diagnostics company focusing on the detection of infectious diseases and genetic disorders. It develops solutions for diagnostics, research, vector control, agriculture, as well as equipment, utilizing the Coprimers, Rapidprobes, Hot Start, and CODX Design technologies. The applications of the products include screenings and detection, multiplexing, SNP (single-nucleotide polymorphism) detection, next-gen sequencing (NGS), and liquid biopsy.
Type
Public
Status
Active
Founded
2013
HQ
Salt Lake City, UT, US | view all locations
Website
https://codiagnostics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Dwight H. Egan, Chief Executive Officer

  • Brian L. Brown

    Brian L. Brown, Chief Financial Officer

  • Mayuranki Modi Almaula

    Mayuranki Modi Almaula, Senior VP, Overseas Operations and Strategic Alliances

  • Richard Abbott, President

    Operating MetricsView all

    Patents (US)

    3

    Q1, 2017

    Patents Pending (US)

    2

    Q1, 2017

    LocationsView all

    2 locations detected

    • Salt Lake City, UT HQ

      United States

      2401 South Foothill Dr, Suite D

    • Vadodara, GJ

      India

      Sarabhai Foundation 1st Floor

    Co-Diagnostics Financials

    Summary Financials

    Revenue (FY, 2025)
    $622.5K
    Gross profit (FY, 2025)
    $400.1K
    Net income (FY, 2025)
    ($46.9M)
    Cash (FY, 2025)
    $11.9M
    EBIT (FY, 2025)
    ($50.2M)
    Enterprise value
    $28.0M

    Footer menu